Japan's Eisai Pharma launches epilepsy drug at India-specific price

摘要

Japanese drug firm, Eisai Pharmaceuticals, has introduced its anti-epileptic drug Fycompa (perampanel) at an India-specific price. Mr. Sanjit Singh Lamba, Managing Director, Eisai Pharmaceuticals India, emphasised the company's intention to have a differential price for the product in India, and said, "The drug is priced at less than $1 per tablet compared to $12 to $15 in the US and Europe. Though the product had received local approval in November 2016, its roll-out had to incorporate the implications of GST, as it had to be imported from their plant in the UK". The drug attracts 12 per cent GST.